| Literature DB >> 33043416 |
E Gkaliagkousi1, E Gavriilaki2, E Yiannaki3, I Vasileiadis4, B Nikolaidou2, A Lazaridis2, P Dolgyras2, S Grigoriadis5, A Triantafyllou2, P Anyfanti2, D Markala3, I Zarifis4, S Douma2.
Abstract
Microvesicles (MVs) have recently emerged as markers of thrombosis. Furthermore, there is an unexplained residual thrombotic risk is observed in patients with acute coronary syndrome (ACS) and/or stable coronary artery disease (CAD), despite treatment. We measured platelet (PMVs) and erythrocyte (ErMVs) in patients with ACS and stable CAD, both in the peripheral and coronary circulation. We studied consecutive eligible patients during a coronary angiography. Blood samples were collected from the stem of the left coronary artery and femoral artery. PMVs were significantly increased in CAD patients compared to controls. ACS patients had also increased PMVs in coronary and peripheral circulation, compared to controls. Furthermore, ACS patients exhibited increased PMVs in coronary compared to peripheral circulation. Lastly, coronary PMVs were associated with the severity of CAD based on the SYNTAX score. No significant differences were observed in the levels of ErMVs among groups. Therefore, PMVs emerge as novel markers of thrombosis in CAD, further augmenting the vicious cycle of inflammation and thrombosis during ACS. Importantly, coronary PMVs may reflect the severity of CAD in this population.Entities:
Keywords: Acute coronary syndrome; Coronary artery disease; Erythrocyte; Microvesicles; Platelet
Mesh：
Substances：
Year: 2020 PMID： 33043416 DOI： 10.1007/s11239-020-02302-5
Source DB: PubMed Journal: J Thromb Thrombolysis ISSN： 0929-5305 Impact factor: 2.300